Method for predicting high cereblon expression using blood markers in multiple myeloma

摘要

The present invention relates to a method for predicting the expression level of cereblon in bone marrow plasma cells of a patient with multiple myeloma using a blood marker and a method for providing information on the prognosis following administration of an immunomodulator for multiple myeloma. it's about Using the method of the present invention, it is possible to predict the high-expression group (25% or more) of cereblon without bone marrow examination, and effectively select patients who are thought to have small (or large) effects on immunotherapy, and based on this, patients with multiple myeloma You can decide whether to administer an immunomodulatory agent or not.